SBIR/STTR Research Award

SBIR Phase II: High-Throughput Specific Cell Loading by Optoinjection

Award identifier 90f0a47ae8b532ae6f51bdfa933ad90e42b1a822333fbb8136cade1af803463cAwarding agency National Science Foundation

Award amount

$500,000

Program and phase

SBIR · Phase II

Award year

2004

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
CYNTELLECT, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

This SBIR Phase II project proposes to develop a novel technology for laser-enabled analysis and processing (LEAP) of living cells. The ability to load cells with compounds is critical in many areas of research and medicine such as drug discovery and gene therapy. Current methods have limitations with respect to specificity, efficiency, toxicity, and/or throughput. Optoinjection is a novel and versatile procedure for cell loading that has been demonstrated in a few laboratories. Unfortunately, this is a slow, laborious procedure carried out on specialized microscopes. Oncosis has developed the LEAP platform for high-speed cell imaging and purification via lethal laser effects on unwanted cells. Phase I results demonstrated feasibility for using the LEAP platform to implement optoinjection in a high-throughput, cell-specific manner that would enable the commercialization of this novel form of cell loading. Phase II studies are proposed to optimize and implement optoinjection in biologically relevant experimental systems, resulting in data supporting this powerful new tool for the analysis and manipulation of living cells within a physiological environment. The instrument design will then be configured for successful commercial manufacturing, and further improvements in capabilities will be pursued in order to maintain market leadership and to expand into other markets. The commercial application of this project is in the areas of cell-based life science research and drug discovery. Over $ 2.6 billion was spent during 2001 on research instrumentation in academic life science research and commercial drug discovery, and growth to $ 5.3 billion by 2005 has been forecasted. For the specific application of optoinjection, LEAP provides many advantages over current techniques including simplicity, robustness, efficiency, speed, high viability, and specificity. The commercial opportunity for this platform is therefore significant, as is the scientific enablement of experimentation that is not currently possible.

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.